921592-79-2

Upstream product

• 1009-36-5 2-chloro-5-nitroanisole 
• 851690-75-0 (R)-1-[2-(methyloxy)-4-nitrophenyl]-3-pyrrolidinol 

Downstream Products

• 851690-21-6 6-(4-chlorophenyl)-3-{4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-methoxyphenyl}thieno[3, 2-d]pyrimidin-4(3H)-one 
• 1221419-44-8 C₂₃H₂₁ClN₄O₃ 
• 921592-80-5 3-amino-5-(4-chlorophenyl)-N-{4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-methoxyphenyl}thiophene-2-carboxamide 

Relevant academic research and scientific papers

THERAPEUTIC AGENTS

Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

3-(4-AMINOPHENYL) THIENOPYRIMID-4-ONE DERIVATIVES AS MCH R1 ANTAGONISTS FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY

This invention relates to novel arylamines which are antagonists of the melanin-concentrating hormone receptor 1 (MCH R1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines for the treatment